Mesoblast Ltd
MESO20.960USD
+1.090+5.49%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
2.68BMarket Cap
LossP/E TTM
More Details of Mesoblast Ltd Company
Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
Mesoblast Ltd Info
Ticker SymbolMESO
Company nameMesoblast Ltd
IPO dateDec 16, 2004
CEOItescu (Silviu)
Number of employees81
Security typeDepository Receipt
Fiscal year-endDec 16
AddressL 38 55 Collins St
CityMELBOURNE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryAustralia
Postal code3000
Phone61396396036
Websitehttps://www.mesoblast.com/
Ticker SymbolMESO
IPO dateDec 16, 2004
CEOItescu (Silviu)
Company Executives of Mesoblast Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Eric A. Rose, M.D.
Dr. Eric A. Rose, M.D.
Executive Director, Chief Medical Officer
Executive Director, Chief Medical Officer
71.47K
+30310.00%
Dr. Silviu Itescu
Dr. Silviu Itescu
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. William M. (Bill) Burns
Mr. William M. (Bill) Burns
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. Peter Howard
Mr. Peter Howard
General Counsel, Corporate Executive
General Counsel, Corporate Executive
--
--
Ms. Geraldine Storton
Ms. Geraldine Storton
Head - Regulatory Affairs and Quality Management
Head - Regulatory Affairs and Quality Management
--
--
Ms. Niva Sivakumar
Ms. Niva Sivakumar
Joint Company Secretary
Joint Company Secretary
--
--
Mr. Philip J. (Phil) Facchina
Mr. Philip J. (Phil) Facchina
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Justin Horst, Ph.D.
Mr. Justin Horst, Ph.D.
Head - Manufacturing
Head - Manufacturing
--
--
Mr. Michael Schuster
Mr. Michael Schuster
Pharma Partnering
Pharma Partnering
--
--
Mr. Philip R. Krause, M.D.
Mr. Philip R. Krause, M.D.
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Eric A. Rose, M.D.
Dr. Eric A. Rose, M.D.
Executive Director, Chief Medical Officer
Executive Director, Chief Medical Officer
71.47K
+30310.00%
Dr. Silviu Itescu
Dr. Silviu Itescu
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. William M. (Bill) Burns
Mr. William M. (Bill) Burns
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. Peter Howard
Mr. Peter Howard
General Counsel, Corporate Executive
General Counsel, Corporate Executive
--
--
Ms. Geraldine Storton
Ms. Geraldine Storton
Head - Regulatory Affairs and Quality Management
Head - Regulatory Affairs and Quality Management
--
--
Ms. Niva Sivakumar
Ms. Niva Sivakumar
Joint Company Secretary
Joint Company Secretary
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Gueck (William J)
5.00%
Legal & General Investment Management Ltd.
0.51%
Morgan Stanley & Co. International Plc
0.32%
Goldman Sachs & Company, Inc.
0.32%
BlackRock Institutional Trust Company, N.A.
0.29%
Other
93.56%
Shareholders
Shareholders
Proportion
Gueck (William J)
5.00%
Legal & General Investment Management Ltd.
0.51%
Morgan Stanley & Co. International Plc
0.32%
Goldman Sachs & Company, Inc.
0.32%
BlackRock Institutional Trust Company, N.A.
0.29%
Other
93.56%
Shareholder Types
Shareholders
Proportion
Individual Investor
5.09%
Investment Advisor
1.52%
Research Firm
0.84%
Investment Advisor/Hedge Fund
0.68%
Bank and Trust
0.03%
Hedge Fund
0.02%
Venture Capital
0.01%
Other
91.81%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
136
3.98M
3.10%
-306.12K
2025Q3
134
3.48M
2.71%
-1.10M
2025Q2
126
4.04M
3.16%
+542.30K
2025Q1
132
4.07M
3.19%
+9.28K
2024Q4
122
3.23M
2.55%
+620.09K
2024Q3
100
1.76M
1.52%
-1.23M
2024Q2
98
1.70M
1.52%
-705.91K
2024Q1
97
1.24M
1.12%
-806.95K
2023Q4
94
840.17K
0.85%
-1.02M
2023Q3
97
766.21K
0.94%
-1.35M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Gueck (William J)
6.42M
5%
+6.42M
--
Sep 12, 2025
Legal & General Investment Management Ltd.
651.42K
0.51%
+651.42K
--
Sep 30, 2025
Morgan Stanley & Co. International Plc
413.52K
0.32%
+100.00K
+31.90%
Sep 30, 2025
Goldman Sachs & Company, Inc.
407.28K
0.32%
-8.19K
-1.97%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
376.17K
0.29%
-122.83K
-24.61%
Sep 30, 2025
Susquehanna International Group, LLP
271.49K
0.21%
+36.90K
+15.73%
Sep 30, 2025
Arax Advisory Partners
200.08K
0.16%
+200.08K
--
Sep 30, 2025
Summit Wealth Strategies
199.29K
0.16%
+1.13K
+0.57%
Jun 30, 2025
UBS Financial Services, Inc.
156.05K
0.12%
-3.99K
-2.49%
Sep 30, 2025
Aperio Group, LLC
137.23K
0.11%
+2.06K
+1.52%
Sep 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Biotechnology ETF
0.1%
Invesco Nasdaq Biotechnology ETF
0.08%
ProShares Ultra Nasdaq Biotechnology
0.08%
ActivePassive International Equity ETF
0.01%
iShares Biotechnology ETF
Proportion0.1%
Invesco Nasdaq Biotechnology ETF
Proportion0.08%
ProShares Ultra Nasdaq Biotechnology
Proportion0.08%
ActivePassive International Equity ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 22, 2023
Merger
2→1
Dec 22, 2023
Merger
2→1
Dec 22, 2023
Merger
2→1
Dec 22, 2023
Merger
2→1
Date
Type
Ratio
Dec 22, 2023
Merger
2→1
Dec 22, 2023
Merger
2→1
Dec 22, 2023
Merger
2→1
Dec 22, 2023
Merger
2→1
FAQs
Who are the top five shareholders of Mesoblast Ltd?
The top five shareholders of Mesoblast Ltd are:
Gueck (William J) holds 6.42M shares, accounting for 5.00% of the total shares.
Legal & General Investment Management Ltd. holds 651.42K shares, accounting for 0.51% of the total shares.
Morgan Stanley & Co. International Plc holds 413.52K shares, accounting for 0.32% of the total shares.
Goldman Sachs & Company, Inc. holds 407.28K shares, accounting for 0.32% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 376.17K shares, accounting for 0.29% of the total shares.
Gueck (William J) holds 6.42M shares, accounting for 5.00% of the total shares.
Legal & General Investment Management Ltd. holds 651.42K shares, accounting for 0.51% of the total shares.
Morgan Stanley & Co. International Plc holds 413.52K shares, accounting for 0.32% of the total shares.
Goldman Sachs & Company, Inc. holds 407.28K shares, accounting for 0.32% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 376.17K shares, accounting for 0.29% of the total shares.
What are the top three shareholder types of Mesoblast Ltd?
The top three shareholder types of Mesoblast Ltd are:
Gueck (William J)
Legal & General Investment Management Ltd.
Morgan Stanley & Co. International Plc
Gueck (William J)
Legal & General Investment Management Ltd.
Morgan Stanley & Co. International Plc
How many institutions hold shares of Mesoblast Ltd (MESO)?
As of 2025Q4, 136 institutions hold shares of Mesoblast Ltd, with a combined market value of approximately 3.98M, accounting for 3.10% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 0.39%.
What is the biggest source of revenue for Mesoblast Ltd?
In --, the -- business generated the highest revenue for Mesoblast Ltd, amounting to -- and accounting for --% of total revenue.
